Analysts expect Agile Therapeutics Inc (NASDAQ:AGRX) to report ($0.10) earnings per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Agile Therapeutics’ earnings. The highest EPS estimate is ($0.08) and the lowest is ($0.14). Agile Therapeutics reported earnings per share of ($0.11) in the same quarter last year, which would suggest a positive year-over-year growth rate of 9.1%. The business is scheduled to report its next earnings report on Thursday, November 7th.
On average, analysts expect that Agile Therapeutics will report full year earnings of ($0.44) per share for the current fiscal year, with EPS estimates ranging from ($0.52) to ($0.39). For the next fiscal year, analysts expect that the company will report earnings of ($0.42) per share, with EPS estimates ranging from ($0.85) to $0.11. Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side research analysts that that provide coverage for Agile Therapeutics.
Agile Therapeutics (NASDAQ:AGRX) last posted its earnings results on Thursday, August 1st. The specialty pharmaceutical company reported ($0.08) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.11) by $0.03.
In related news, CEO Alfred Altomari purchased 20,000 shares of the firm’s stock in a transaction dated Monday, June 10th. The stock was bought at an average price of $1.27 per share, for a total transaction of $25,400.00. Following the purchase, the chief executive officer now directly owns 258,568 shares in the company, valued at approximately $328,381.36. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 8.50% of the company’s stock.
Hedge funds have recently modified their holdings of the company. BlackRock Inc. increased its stake in shares of Agile Therapeutics by 15.7% during the 4th quarter. BlackRock Inc. now owns 133,219 shares of the specialty pharmaceutical company’s stock worth $77,000 after purchasing an additional 18,038 shares during the last quarter. Acadian Asset Management LLC increased its stake in shares of Agile Therapeutics by 33.3% during the 1st quarter. Acadian Asset Management LLC now owns 417,269 shares of the specialty pharmaceutical company’s stock worth $630,000 after purchasing an additional 104,222 shares during the last quarter. Finally, Geode Capital Management LLC increased its stake in shares of Agile Therapeutics by 24.0% during the 4th quarter. Geode Capital Management LLC now owns 230,496 shares of the specialty pharmaceutical company’s stock worth $132,000 after purchasing an additional 44,639 shares during the last quarter. Institutional investors own 42.38% of the company’s stock.
Shares of Agile Therapeutics stock traded down $0.11 during mid-day trading on Friday, hitting $1.00. 2,929,613 shares of the stock were exchanged, compared to its average volume of 220,383. The firm’s 50-day moving average is $1.37. The company has a quick ratio of 8.91, a current ratio of 8.91 and a debt-to-equity ratio of 0.01. Agile Therapeutics has a 12 month low of $0.23 and a 12 month high of $1.70.
About Agile Therapeutics
Agile Therapeutics, Inc, a women's healthcare company, focuses on the development and commercialization of prescription contraceptive products for women. Its lead product candidate is Twirla, also known as AG200-15, a once-weekly prescription contraceptive patch, which completed Phase III clinical trials.
Recommended Story: What is Forex?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Agile Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.